The Coexistence of extended spectrum β lactamases and AmpC production among uropathogenic isolates of Escherichia coli and its antibiogram pattern

   Emergence of drug resistance in Escherichia coli due to various mechanisms makes the treatment choices very limited. The objective of this research was to investigate extended-spectrum beta-lactamases (ESBLs) and AmpC lactamases in E. coli isolates from urinary tract infections (UTIs) and to assess their antibacterial susceptibility patterns in a health-care context. A total of 70 E. coli isolates from clinically assumed cases of UTI patients during the 9 months period. The isolates with bacteriuria (105 CFU/ml) were identified. ESBL and AmpC were detected phenotypically. Out of the 70 isolates of uropathogenic E. coli, ESBL production was detected in 34 (48.6%) isolates and AmpC producer in 27 (38.6%) of isolates in which 14 (20%) of them showed coexistence phenotype of both ESBLs and AmpC and 23 (32.9%) E. coli isolates were both ESBL and AmpC non-producer. The findings donated information regarding drug resistance. The level of resistance recorded in ESBL- and AmpC-producing uropathogenic E. coli of this study was raising; therefore, it is crucial to have a strict infection control measures and routine monitoring of ESBL- and AmpC-producing bacteria in clinical laboratory.